New Perspectives of Central Nervous System Injury and Neuroprotection - 1st Edition - ISBN: 9780123869869, 9780123870162

New Perspectives of Central Nervous System Injury and Neuroprotection, Volume 102

1st Edition

Serial Volume Editors: Hari Shanker Sharma
Hardcover ISBN: 9780123869869
eBook ISBN: 9780123870162
Imprint: Academic Press
Published Date: 10th July 2012
Page Count: 424
Tax/VAT will be calculated at check-out
204.00
124.00
155.00
212.68
Unavailable
Compatible Not compatible
VitalSource PC, Mac, iPhone & iPad Amazon Kindle eReader
ePub & PDF Apple & PC desktop. Mobile devices (Apple & Android) Amazon Kindle eReader
Mobi Amazon Kindle eReader Anything else

Institutional Access


Table of Contents

  • Series Page
  • Contributors
  • Preface
  • Acknowledgments
  • Chapter 1 The Function and Mechanisms of Nurr1 Action in Midbrain Dopaminergic Neurons, from Development and Maintenance to Survival
    • I Introduction
    • II The Midbrain Dopamine System: Neurochemistry
    • III The Midbrain Dopamine System: Development
    • IV Dopaminergic Neurons and Parkinson’s Disease
    • V Nurr1, A Protein Whose Function Is Important in the Life Cycle of VM DANs
    • VI The Mechanisms of Nurr1 as a Nuclear Receptor
    • VII Most Recent Development in Application of Nurr1 in Dopaminergic Differentiation and Implications in Future Treatment for PD
  • Chapter 2 Monoclonal Antibodies as Novel Neurotherapeutic Agents in CNS Injury and Repair
    • I Introduction
    • II Historical Perspectives on the Use of Antibodies as Therapy
    • III Therapeutic Basis of Antibodies
    • IV Antibodies Versus Receptor Antagonist Drugs
    • V Antibodies Neutralize Effects of Endogenous Antigens
    • VI Our Investigations on Monoclonal Antibodies to Induce Neuroprotection in CNS Injuries
    • VII Neuroprotective Effects of Serotonin Antibodies in CNS Injuries
    • VIII Neuroprotection by Dynorphin A Antibodies in CNS Injuries
    • IX Antibodies to nNOS Is Neuroprotective in CNS Injuries
    • X TNF-α Antibodies Are Neuroprotective in CNS Injuries
    • XI Combination of nNOS and TNF-α Antibodies Enhances Neuroprotection in SCI
    • XII Conclusion and Future Perspectives
  • Chapter 3 The Blood–Brain Barrier in Alzheimer’s Disease
    • I Introduction
    • II Pathology of AD
    • III A Receptor-Mediated Transport of apoJ and ABP at the BBB and BCSF-B
    • IV Human Receptors for ABP1-40
    • V Clearance of AB1-40 P from Brain LDL Receptor at the BBB
    • VI Clearance of ABP1-40 in Monkey Model
    • VII Point Mutation of Codon 22 Reduces Clearance of ABP1-40 from the CSF and Prevents Transport from CNS to Blood
    • VIII Circulating ABP Crosses the BBB in Aged Monkeys
    • IX Cerebrovascular Pathology in AD
    • X Existing Theories Regarding Origin of ABP
    • XI Conclusion
  • Chapter 4 Neurovascular Aspects of Amyotrophic Lateral Sclerosis
    • I Introduction
    • II BBB/BSCB Impairment in ALS
    • III Future Perspectives
    • IV Conclusion
  • Chapter 5 Quercetin in Hypoxia-Induced Oxidative Stress: Novel Target for Neuroprotection
    • I Introduction
    • II Hypoxia and Free Radical Generation
    • III Brain: Target to Free Radical Damage
    • IV Antioxidant Defense System
    • V Antioxidant Defense System and Hypoxia
    • VI Pathophysiological Changes in Brain in Response to Hypoxia
    • VII Antioxidant Therapy
    • VIII Our Investigation on Neuroprotection Elicited by Quercetin
    • X General Conclusion and Future Perspective
  • Chapter 6 Environmental Conditions Modulate Neurotoxic Effects of Psychomotor Stimulant Drugs of Abuse
    • I Introduction
    • II Brain Temperature Responses to METH and MDMA are Modulated by Activity State and Environmental Conditions
    • III Adverse Environmental Conditions Enhance Histochemical and Morphological Perturbations Induced by METH: Role of Brain Temperature
    • IV Temperature Modulation of BBB Permeability
    • V Conclusions and Perspectives
  • Chapter 7 Central Nervous Tissue Damage after Hypoxia and Reperfusion in Conjunction with Cardiac Arrest and Cardiopulmonary Resuscitation
    • I Introduction
  • Chapter 8 Interactions Between Opioids and Anabolic Androgenic Steroids: Implications for the Development of Addictive Behavior
    • I Introduction
    • II AAS May Lead to Opioid Dependence
    • III Interactions Between AAS and the Endogenous Opioids
    • IV AAS Dependence Involve Opioid Mechanisms
    • V Conclusions
  • Chapter 9 Neurotrophic Factors and Neurodegenerative Diseases
    • I Introduction
    • II NTFs and Neurodegenerative Diseases
    • III NTF Delivery Approaches: Evolution in Therapies
    • IV Conclusion
  • Chapter 10 Neuroprotective Effects of Cerebrolysin, A Combination of Different Active Fragments of Neurotrophic Factors And Peptides on the Whole Body Hyperthermia-Induced Neurotoxicity
    • I Introduction
    • II Blood–Brain Barrier—A Gateway to Brain Diseases
    • III Factors Affecting Hyperthermia-Induced Brain Damage
    • IV Cerebrolysin, a Novel Therapeutic Agent in Hyperthermia-Induced Neurotoxicity
    • V Functional Significance of These Findings
    • VI Conclusions
    • VII Future Perspectives
  • Chapter 11 Alzheimer’s Disease and Amyloid: Culprit or Coincidence?
    • I Introduction
    • II Amyloid and AD
    • III Tau and AD
    • IV AD and Tau: A Double Act?
    • V White Matter Pathology and AD
    • VI Transgenic Animal Models for AD: What Have They Taught Us?
    • VII Oxidative Stress and AD
    • VIII Inflammation and AD
    • IX Other Amyloid-Independent Mechanisms in AD
    • X Future Perspectives
  • Chapter 12 Vascular Endothelial Growth Factor and Other Angioglioneurins
    • I Introduction
    • II VEGF
    • III Other Angioglioneurins
    • IV Potential Role of VEGF and Other Angioglioneurins in Brain Restoration
    • V Conclusions
  • Subject Index
  • Contents of Recent Volumes

Description

  • Series Page
  • Contributors
  • Preface
  • Acknowledgments
  • Chapter 1 The Function and Mechanisms of Nurr1 Action in Midbrain Dopaminergic Neurons, from Development and Maintenance to Survival
    • I Introduction
    • II The Midbrain Dopamine System: Neurochemistry
    • III The Midbrain Dopamine System: Development
    • IV Dopaminergic Neurons and Parkinson’s Disease
    • V Nurr1, A Protein Whose Function Is Important in the Life Cycle of VM DANs
    • VI The Mechanisms of Nurr1 as a Nuclear Receptor
    • VII Most Recent Development in Application of Nurr1 in Dopaminergic Differentiation and Implications in Future Treatment for PD
  • Chapter 2 Monoclonal Antibodies as Novel Neurotherapeutic Agents in CNS Injury and Repair
    • I Introduction
    • II Historical Perspectives on the Use of Antibodies as Therapy
    • III Therapeutic Basis of Antibodies
    • IV Antibodies Versus Receptor Antagonist Drugs
    • V Antibodies Neutralize Effects of Endogenous Antigens
    • VI Our Investigations on Monoclonal Antibodies to Induce Neuroprotection in CNS Injuries
    • VII Neuroprotective Effects of Serotonin Antibodies in CNS Injuries
    • VIII Neuroprotection by Dynorphin A Antibodies in CNS Injuries
    • IX Antibodies to nNOS Is Neuroprotective in CNS Injuries
    • X TNF-α Antibodies Are Neuroprotective in CNS Injuries
    • XI Combination of nNOS and TNF-α Antibodies Enhances Neuroprotection in SCI
    • XII Conclusion and Future Perspectives
  • Chapter 3 The Blood–Brain Barrier in Alzheimer’s Disease
    • I Introduction
    • II Pathology of AD
    • III A Receptor-Mediated Transport of apoJ and ABP at the BBB and BCSF-B
    • IV Human Receptors for ABP1-40
    • V Clearance of AB1-40 P from Brain LDL Receptor at the BBB
    • VI Clearance of ABP1-40 in Monkey Model
    • VII Point Mutation of Codon 22 Reduces Clearance of ABP1-40 from the CSF and Prevents Transport from CNS to Blood
    • VIII Circulating ABP Crosses the BBB in Aged Monkeys
    • IX Cerebrovascular Pathology in AD
    • X Existing Theories Regarding Origin of ABP
    • XI Conclusion
  • Chapter 4 Neurovascular Aspects of Amyotrophic Lateral Sclerosis
    • I Introduction
    • II BBB/BSCB Impairment in ALS
    • III Future Perspectives
    • IV Conclusion
  • Chapter 5 Quercetin in Hypoxia-Induced Oxidative Stress: Novel Target for Neuroprotection
    • I Introduction
    • II Hypoxia and Free Radical Generation
    • III Brain: Target to Free Radical Damage
    • IV Antioxidant Defense System
    • V Antioxidant Defense System and Hypoxia
    • VI Pathophysiological Changes in Brain in Response to Hypoxia
    • VII Antioxidant Therapy
    • VIII Our Investigation on Neuroprotection Elicited by Quercetin
    • X General Conclusion and Future Perspective
  • Chapter 6 Environmental Conditions Modulate Neurotoxic Effects of Psychomotor Stimulant Drugs of Abuse
    • I Introduction
    • II Brain Temperature Responses to METH and MDMA are Modulated by Activity State and Environmental Conditions
    • III Adverse Environmental Conditions Enhance Histochemical and Morphological Perturbations Induced by METH: Role of Brain Temperature
    • IV Temperature Modulation of BBB Permeability
    • V Conclusions and Perspectives
  • Chapter 7 Central Nervous Tissue Damage after Hypoxia and Reperfusion in Conjunction with Cardiac Arrest and Cardiopulmonary Resuscitation
    • I Introduction
  • Chapter 8 Interactions Between Opioids and Anabolic Androgenic Steroids: Implications for the Development of Addictive Behavior
    • I Introduction
    • II AAS May Lead to Opioid Dependence
    • III Interactions Between AAS and the Endogenous Opioids
    • IV AAS Dependence Involve Opioid Mechanisms
    • V Conclusions
  • Chapter 9 Neurotrophic Factors and Neurodegenerative Diseases
    • I Introduction
    • II NTFs and Neurodegenerative Diseases
    • III NTF Delivery Approaches: Evolution in Therapies
    • IV Conclusion
  • Chapter 10 Neuroprotective Effects of Cerebrolysin, A Combination of Different Active Fragments of Neurotrophic Factors And Peptides on the Whole Body Hyperthermia-Induced Neurotoxicity
    • I Introduction
    • II Blood–Brain Barrier—A Gateway to Brain Diseases
    • III Factors Affecting Hyperthermia-Induced Brain Damage
    • IV Cerebrolysin, a Novel Therapeutic Agent in Hyperthermia-Induced Neurotoxicity
    • V Functional Significance of These Findings
    • VI Conclusions
    • VII Future Perspectives
  • Chapter 11 Alzheimer’s Disease and Amyloid: Culprit or Coincidence?
    • I Introduction
    • II Amyloid and AD
    • III Tau and AD
    • IV AD and Tau: A Double Act?
    • V White Matter Pathology and AD
    • VI Transgenic Animal Models for AD: What Have They Taught Us?
    • VII Oxidative Stress and AD
    • VIII Inflammation and AD
    • IX Other Amyloid-Independent Mechanisms in AD
    • X Future Perspectives
  • Chapter 12 Vascular Endothelial Growth Factor and Other Angioglioneurins
    • I Introduction
    • II VEGF
    • III Other Angioglioneurins
    • IV Potential Role of VEGF and Other Angioglioneurins in Brain Restoration
    • V Conclusions
  • Subject Index
  • Contents of Recent Volumes

Key Features

  • Reviews written by experts in such a way that provides basic knowledge for beginners and advanced information for researchers and experts
  • New aspects of Neurodegenerative diseases such as; Alzheimer’s Disease, Parkinson’s Disease, Amyotrophic Lateral Sclerosis are presented with the latest therapeutic measures
  • Exacerbation of brain pathology in hypertension or diabetes is discussed for the first time

Readership

Neuroscientists, neurologists, psychologists


Details

No. of pages:
424
Language:
English
Copyright:
© Academic Press 2012
Published:
Imprint:
Academic Press
eBook ISBN:
9780123870162
Hardcover ISBN:
9780123869869

Reviews

Praise for International Review of Neurobiology:
"Invaluable reading." --NATURE

"A valuable addition to any library as current reference material for advanced undergraduates, graduate students, and professional scientists." --CHOICE


About the Serial Volume Editors

Hari Shanker Sharma Serial Volume Editor